Cost-effectiveness of Sativex in multiple sclerosis spasticity: New data and application to Italy

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 15, Issue 3, 2015, Pages 379-391

  Slof, John ^a   Ruiz, Leonardo ^b   Vila, Carlos ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Almirall ^*  (Spain)

Author keywords

cost effectiveness; Italy; multiple sclerosis; Sativex; spasticity

Indexed keywords

NABIXIMOLS; PLANT EXTRACT; TETRAHYDROCANNABINOL-CANNABIDIOL COMBINATION;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DRUG COST; DRUG EFFICACY; DRUG USE; HUMAN; ITALY; MULTIPLE SCLEROSIS; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SPASTICITY; COST BENEFIT ANALYSIS; COST OF ILLNESS; ECONOMICS; HEALTH CARE DELIVERY; MUSCLE SPASTICITY; PATHOPHYSIOLOGY; PROBABILITY; QUALITY ADJUSTED LIFE YEAR;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; HUMANS; ITALY; MARKOV CHAINS; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; PLANT EXTRACTS; QUALITY-ADJUSTED LIFE YEARS;

EID: 84929236373     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2015.1025759     Document Type: Article

References (57)

1. Kister I, Bacon TE, Chamot E, et al. Natural history of multiple sclerosis symptoms. Int J MS Care 2013;15:146-58
2. Arroyo R, Vila C, Dechant KL. Impact of Sativex on quality of life and activities of daily living in patients with multiple sclerosis spasticity. J Comp Eff Res 2014;3:435-44
3. Zwibel HL. Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis. Adv Ther 2009;26(12):1043-57
4. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006;77:918-26
5. Bavikatte G, Gaber T. Approach to spasticity in general practice. Br J Med Pract 2009;2(3):29-34
6. Haselkorn JK, Balsdon Richer C, Fry Welch D; Multiple Sclerosis Council for Clinical Practice Guidelines. Overview of spasticity management in multiple sclerosis. Evidence-based management strategies for spasticity treatment in multiple sclerosis. J Spinal Cord Med 2005;28(2):167-99
7. Stevenson VL. Rehabilitation in practice: spasticity management. Clin Rehabil 2010;24:293-304
8. Perez J. Combined cannabinoid therapy via an oromucosal spray. Drugs Today(Barc) 2006;42:495-501
9. Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, placebo-controlled study on 160 patients. Mult Scler 2004;10:434-41
10. Collin C, Davies P, Mutiboko IK, et al. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007;14: 290-6
11. Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 2010;12:S111-12
12. Wade DT, Collin C, Stott C, Duncombe P. Meta-analysis of the effects of Sativex (nabiximols) on spasticity associated with multiple sclerosis. Mult Scler 2010;16(6): 707-14
13. Novotna A, Mares J, Ratcliffe S, et al. A randomised, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011;18(9):1122-31
14. Lu L, Pearce H, Roome C, et al. Cost effectiveness of oromucosal cannabis-based medicine (Sativex) for spasticity in multiple sclerosis. Pharmacoeconomics 2012;30(12):1157-71
15. Slof J, Gras A. Sativex in multiple sclerosis spasticity: a cost-effectiveness model. Expert Rev Pharmacoecon Outcomes Res 2012;12(4):525-38
16. All Wales Therapeutics and Toxicology Centre. AWMSG Secretariat Assessment Report. Delta-9-tetrahydrocannabinol/ cannabidiol (Sativex) 2.7 mg/2.5 mg oromucosal spray.; Reference number 644 (July 2014)
17. National Clinical Guideline Centre. Multiple sclerosis: Management of multiple sclerosis in primary and secondary care. Clinical guideline 186; National Institute for Health and Care Excellence (UK), London; 2014
18. Sativex oromucosal spray: summary of product characteristics. Almirall; Spain: 2010
19. Arroyo R, Vila C, Clissold S. Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the "5E" study. Expert Rev Pharmacoecon Outcomes Res 2011; 11(2):205-13
20. Craig BA, Sendi PP. Estimation of the transition matrix of a discrete-time Markov chain. Health Econ 2002;11:33-42
21. Istituto Nazionale di Statistica. Available from: www.demo.istat.it [Last accessed January 2015]
22. Flachenecker P, Henze T, Zettl UK. Nabiximols (THC/CBD oromucosal spray, Sativex) in clinical practice-results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity. Eur Neurol 2014; 71(5-6):271-9
23. Flachenecker P, Henze T, Zettl UK. Long-term effectiveness and safety of Sativex (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice. Eur Neurol 2014;72(1-2):95-102
24. Zettl UK, Henze T, Essner U, Flachenecker P. Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I). Eur J Health Econ 2014;15(9): 953-66
25. Svensson J, Borg S, Nilsson P. Costs and quality of life in multiple sclerosis patients with spasticity. Acta Neurol Scand 2014; 129(1):13-20
26. Gazzetta Ufficiale Repubblica Italiana. Serie generale n. 23. Supplemento ordinario n. 8 (2013)
27. Associazione Italiana Fisioterapisti. Tariffario nazionale di minima consigliato per gli onorari delle prestazioni di valutazione, riabilitazione, terapia fisica e strumentale. Valutazione Fisioterapica. Available from: www.aificampania.it [Last accessed January 2015]
28. Federazione Nazionala Collegi IPASVI. Nomenclatore tariffario nazionale. Available from: www.ipasvinovara.it [Last accessed January 2015]
29. Ministero della Salute. Progetto Mattoni SSN. Pronto Soccorso e sistema 118. Available from: www.nsis.salute.gov.it [Last accessed January 2015]
30. Farmadati. Available from: http://www. farmadati.it [Last accessed January 2015]
31. Gazzetta Ufficiale della Repubblica Italiana. Available from: www.gazzettaufficiale.it/eli/ id/2013/04/30/13A03504/sg [Last accessed January 2015]
32. Nance P, Schryvers O, Schmidt B, et al. Intrathecal baclofen therapy for adults with spinal spasticity: therapeutic efficacy and effect on hospital admissions. Can J Neurol Sci 1995;22(1):22-9
33. Ordia JI, Fischer E, Adamski E, Spatz EL. Chronic intrathecal delivery of baclofen by a programmable pump for the treatment of severe spasticity. J Neurosurg 1996;85(3): 452-7
34. Becker WJ, Harris CJ, Long ML, et al. Long-term intrathecal baclofen therapy in patients with intractable spasticity. Can J Neurol Sci 1995;22(3):208-17
35. Hsieh JC, Penn RD. Intrathecal baclofen in the treatment of adult spasticity. Neurosurg Focus 2006;21:1-6
36. Erwin A, Gudesblatt M, Bethoux F, et al. Intrathecal baclofen in multiple sclerosis: too little, too late? Mult Scler 2011;17: 623-9
37. Centro Studi Assobiomedica. Il sistema tariffari per le prestazioni di assistenza ospedaliera. Analisi n.10 (2010)
38. Medtronic, Inc. 2011 Medtronic Product Performance Report. 2011. Available from: http://professional.medtronic.com/wcm/ groups/mdtcomsg/@mdt/@neuro/ documents/documents/2011-neuro-ppr.pdf [Last accessed January 2015]
39. Arroyo R, Massana M, Vila C. Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE study. Int J Neurosci 2013; 123(12):850-8
40. Notcutt WG. A questionnaire survey of patients and carers of patients prescribed Sativex as an unlicensed medicine. Prim Health Care Res Dev 2013;14:192-9
41. Flachenecker P, Zettl U, Henze T. THC: CBD oromucosal spray (nabiximols) in the long term treatment of multiple sclerosis spasticity. The MOVE 2 long-term study. Mult Scler 2013;19(S1):P1121, 527
42. Farrar J, Troxel AB, Stott C, et al. Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin Ther 2008; 30(5):974-85
43. Wade DT, Makela PM, House H, et al. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006;12(5):639-45
44. Eltayb A, Etges T, Wright S. An observational post-approval registry study of patients prescribed Sativex. Results from clinical practice. Mult Scler 2013;19(S1): P1041; 480
45. Serpel MG, Notcutt W, Collin C. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. J Neurol 2013;260:286-95
46. Notcutt W, Langford R, Davies P, et al. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex (nabiximols). Mult Scler 2012;18: 219-28
47. Farrell RA, Flisher L, Broome K, et al. Sativex: an alternative to intrathecal baclofen in patients with severe multiple sclerosis-related spasticity? Mult Scler 2013; 19(S1):P650; 284
48. Delhaas EM, Beersen N, Redekop WK, Klazinga NS. Long-term outcomes of continuous intrathecal baclofen infusion for treatment of spasticity: a prospective multicenter follow-up study. Neuromodulation 2008;11(3):227-36
49. Kesselring J. Evidence-based medicine and multiple sclerosis: figures and stories. Neuroepidemiology 2010;35(2):100
50. Sobocki P, Pugliatti M, Lauer K, Kobelt G. Estimation of the cost of MS in Europe: extrapolations from a multinational cost study. Mult Scler 2007;13(8):1054-64
51. Koehler J, Feneberg W, Gorodetzky H, et al. Clinical experiences with on-label nabiximols therapy in multiple sclerosis induced spasticity. Mult Scler 2013;19(S1): P646; 281-282
52. Wright S, Vachova MM, Novakova I. The effect of long-term treatment with a prescription cannabis based THC: CBD oromucosal spray on cognitive function and mood: a 12 month double blind placebo-controlled study in people with spasticity due to multiple sclerosis. Mult Scler 2013;19(S1):P1206; 572
53. Paolino I, Medici D, Zagaglia S, et al. Clinical and electrophysiological measures in a cohort of multiple sclerosis patients during treatment with nabiximols for spasticity. Mult Scler 2013;19(S1):P645; 281
54. Freidel M, Tiel-Wilck K, Schreiber H, et al. Resistant multiple sclerosis spasticity (MSS) treatment with THC:CBD spray and effects on driving ability. Mult Scler 2013;19(S1): P1111, 522
55. Ferrè L, Sorosina M, Santoro S, et al. Efficacy, safety and response rate of nabiximols assessed in an Italian monocentric cohort. Mult Scler 2014; 20(S1):P920, 469
56. Lorente Fernández L, Monte Boquet E, Perez-Miralles F, et al. Clinical experiences with cannabinoids in spasticity management in multiple sclerosis. Neurología 2014; 29(5):257-60
57. Arnal C, Carrion F. Structured diagnosis and management with THC:CBD oromucosal spray of patients with resistant multiple sclerosis spasticity. Mult Scler 2013;19(S1):P1110; 522